Home Protein Tyrosine Kinase Pyk2

Pyk2

Pyk2 Products

  • All (8)
  • Pyk2 Inhibitors (8)
  • New Pyk2 Products
Catalog No. Product Name Information Product Use Citations Product Validations
S2890 PF-562271 PF-562271 (PF-00562271) is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM in cell-free assays, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs.
Heliyon, 2024, 10(1):e23690
Nat Commun, 2023, 14(1):6270
Nat Commun, 2023, 14(1):6270
S8032 PRT062607 (P505-15) HCl PRT062607 (P505-15, BIIB057, PRT-2607) HCl is a novel, highly selective Syk inhibitor with IC50 of 1 nM in cell-free assays, >80-fold selective for Syk than Fgr, PAK5, Lyn, FAK, Pyk2, FLT3, MLK1 and Zap70.
Sci Rep, 2024, 14(1):7739
J Exp Med, 2023, 220(9)e20230054
J Exp Med, 2023, 220(9)e20230054
S7357 PF-562271 HCl PF-562271 HCl is the hydrochloride salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.
Nat Cardiovasc Res, 2023, 2(6):550-571
Front Immunol, 2022, 13:837180
Cancers (Basel), 2022, 14(6)1537
S2672 PF-562271 Besylate PF-562271 Besylate is the benzenesulfonate salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.
Elife, 2023, 12RP89141
Elife, 2023, 12RP89141
bioRxiv, 2023, 2023.06.02.543509
S2820 TAE226 (NVP-TAE226) TAE226 (NVP-TAE226) is a potent FAK inhibitor with IC50 of 5.5 nM and modestly potent to Pyk2, ~10- to 100-fold less potent against InsR, IGF-1R, ALK, and c-Met. TAE226 (NVP-TAE226) induces apoptosis.
Theranostics, 2022, 12(3):1097-1116
Proc Natl Acad Sci U S A, 2022, 119(32):e2201328119
Cancer Res Treat, 2022, 54(3):767-781
S7644 PF-431396 PF-431396 is a dual PYK2/FAK inhibitor with IC50 of 11 nM and 2 nM, respectively.
Nat Commun, 2023, 14(1):6270
Nat Commun, 2023, 14(1):6270
Cell Rep, 2023, 42(5):112529
E1961New NVL-655 NVL-655 is a selective inhibitor of anaplastic lymphoma kinase (ALK), with potential antineoplastic activity in the Ba/F3 xenograft model. It also exhibits significant inhibitory activity against ROS1, LTK, PYK2, TRKB, and FAK, with an IC50 ≤10-fold ALK and demonstrates high potency against specific ALK mutations, with an IC50 of <0.73 nM, 7 nM, 3 nM, 3 nM for G1202R, G1202R/L1196M, G1202R/G1269A and G1202R/L1198F respectively.
E1783New Conteltinib(CT-707) Conteltinib(CT-707) is a potent multikinase inhibitor of ALK, FAK,Pyk2, showing promising anti-tumor activities. Conteltinib exhibits significant inhibitory effects on FAK with an IC50 value of 1.6 nM in vitro kinase assay.
S2890 PF-562271 PF-562271 (PF-00562271) is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM in cell-free assays, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs.
Heliyon, 2024, 10(1):e23690
Nat Commun, 2023, 14(1):6270
Nat Commun, 2023, 14(1):6270
S8032 PRT062607 (P505-15) HCl PRT062607 (P505-15, BIIB057, PRT-2607) HCl is a novel, highly selective Syk inhibitor with IC50 of 1 nM in cell-free assays, >80-fold selective for Syk than Fgr, PAK5, Lyn, FAK, Pyk2, FLT3, MLK1 and Zap70.
Sci Rep, 2024, 14(1):7739
J Exp Med, 2023, 220(9)e20230054
J Exp Med, 2023, 220(9)e20230054
S7357 PF-562271 HCl PF-562271 HCl is the hydrochloride salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.
Nat Cardiovasc Res, 2023, 2(6):550-571
Front Immunol, 2022, 13:837180
Cancers (Basel), 2022, 14(6)1537
S2672 PF-562271 Besylate PF-562271 Besylate is the benzenesulfonate salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.
Elife, 2023, 12RP89141
Elife, 2023, 12RP89141
bioRxiv, 2023, 2023.06.02.543509
S2820 TAE226 (NVP-TAE226) TAE226 (NVP-TAE226) is a potent FAK inhibitor with IC50 of 5.5 nM and modestly potent to Pyk2, ~10- to 100-fold less potent against InsR, IGF-1R, ALK, and c-Met. TAE226 (NVP-TAE226) induces apoptosis.
Theranostics, 2022, 12(3):1097-1116
Proc Natl Acad Sci U S A, 2022, 119(32):e2201328119
Cancer Res Treat, 2022, 54(3):767-781
S7644 PF-431396 PF-431396 is a dual PYK2/FAK inhibitor with IC50 of 11 nM and 2 nM, respectively.
Nat Commun, 2023, 14(1):6270
Nat Commun, 2023, 14(1):6270
Cell Rep, 2023, 42(5):112529
E1961New NVL-655 NVL-655 is a selective inhibitor of anaplastic lymphoma kinase (ALK), with potential antineoplastic activity in the Ba/F3 xenograft model. It also exhibits significant inhibitory activity against ROS1, LTK, PYK2, TRKB, and FAK, with an IC50 ≤10-fold ALK and demonstrates high potency against specific ALK mutations, with an IC50 of <0.73 nM, 7 nM, 3 nM, 3 nM for G1202R, G1202R/L1196M, G1202R/G1269A and G1202R/L1198F respectively.
E1783New Conteltinib(CT-707) Conteltinib(CT-707) is a potent multikinase inhibitor of ALK, FAK,Pyk2, showing promising anti-tumor activities. Conteltinib exhibits significant inhibitory effects on FAK with an IC50 value of 1.6 nM in vitro kinase assay.
E1961New NVL-655 NVL-655 is a selective inhibitor of anaplastic lymphoma kinase (ALK), with potential antineoplastic activity in the Ba/F3 xenograft model. It also exhibits significant inhibitory activity against ROS1, LTK, PYK2, TRKB, and FAK, with an IC50 ≤10-fold ALK and demonstrates high potency against specific ALK mutations, with an IC50 of <0.73 nM, 7 nM, 3 nM, 3 nM for G1202R, G1202R/L1196M, G1202R/G1269A and G1202R/L1198F respectively.
E1783New Conteltinib(CT-707) Conteltinib(CT-707) is a potent multikinase inhibitor of ALK, FAK,Pyk2, showing promising anti-tumor activities. Conteltinib exhibits significant inhibitory effects on FAK with an IC50 value of 1.6 nM in vitro kinase assay.

Choose Selective Pyk2 Inhibitors

Tags: Pyk2 inhibitor|Pyk2 agonist|Pyk2 activator|Pyk2 inducer|Pyk2 antagonist|Pyk2 signaling pathway|Pyk2 assay kit